Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ; Cancer Prevention Network.

Gastroenterology. 2012 Oct;143(4):917-26.e1. doi: 10.1053/j.gastro.2012.06.044. Epub 2012 Jul 11.

2.

The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus.

Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Weston A.

Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005.

3.

Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.

Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA; Chemoprevention for Barrett's Esophagus Trial Research Group.

J Natl Cancer Inst. 2007 Apr 4;99(7):545-57.

4.

Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.

Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G.

Gastroenterology. 2002 Jul;123(1):60-7.

PMID:
12105834
5.
6.

Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.

Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW.

Am J Gastroenterol. 2006 Sep;101(9):1964-71. Epub 2006 Jul 18.

PMID:
16848802
7.

Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.

de Bortoli N, Martinucci I, Piaggi P, Maltinti S, Bianchi G, Ciancia E, Gambaccini D, Lenzi F, Costa F, Leonardi G, Ricchiuti A, Mumolo MG, Bellini M, Blandizzi C, Marchi S.

Aliment Pharmacol Ther. 2011 May;33(9):1019-27. doi: 10.1111/j.1365-2036.2011.04616.x. Epub 2011 Mar 8.

8.

Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.

Yachimski P, Mino-Kenudson M, Sherwood ME, Puricelli WP, Nishioka NS, Lauwers GY.

Virchows Arch. 2011 Dec;459(6):581-6. doi: 10.1007/s00428-011-1167-x. Epub 2011 Nov 13.

PMID:
22081106
9.

Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.

Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC.

Aliment Pharmacol Ther. 2008 Feb 15;27(4):321-6. Epub 2007 Nov 28.

10.

Is 325 mg of prevention worth a pound of cure?

Inadomi JM.

Gastroenterology. 2012 Oct;143(4):885-7. doi: 10.1053/j.gastro.2012.08.015. Epub 2012 Aug 20. No abstract available.

PMID:
22917867
11.

[Medical treatment of Barrett's esophagus].

Kinoshita Y, Yuki T.

Nihon Rinsho. 2005 Aug;63(8):1449-53. Review. Japanese.

PMID:
16101238
12.

Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.

Brown CS, Lapin B, Wang C, Goldstein JL, Linn JG, Denham W, Haggerty SP, Talamonti MS, Howington JA, Carbray J, Ujiki MB.

Surg Endosc. 2015 Dec;29(12):3528-34. doi: 10.1007/s00464-015-4103-3. Epub 2015 Feb 13.

PMID:
25676204
13.

Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ; Probar-study Group.

Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. doi: 10.1053/j.gastro.2011.08.036. Epub 2011 Aug 28.

PMID:
21878200
14.

COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.

Villanacci V, Rossi E, Zambelli C, Galletti A, Cestari R, Missale G, Casa DD, Bassotti G.

Dig Liver Dis. 2007 Apr;39(4):305-11. Epub 2007 Feb 16.

PMID:
17307036
15.

The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.

Abu-Sneineh A, Tam W, Schoeman M, Fraser R, Ruszkiewicz AR, Smith E, Drew PA, Dent J, Holloway RH.

Aliment Pharmacol Ther. 2010 Oct;32(8):1023-30. doi: 10.1111/j.1365-2036.2010.04428.x. Epub 2010 Aug 15.

16.

Surveillance in Barrett's esophagus: an audit of practice.

Ajumobi A, Bahjri K, Jackson C, Griffin R.

Dig Dis Sci. 2010 Jun;55(6):1615-21. doi: 10.1007/s10620-009-0917-y. Epub 2009 Aug 11.

PMID:
19669878
17.

Chemoprevention and Barrett's esophagus: decisions, decisions.

Falk GW, Jankowski J.

Am J Gastroenterol. 2008 Oct;103(10):2443-5. doi: 10.1111/j.1572-0241.2008.02129.x. Epub 2008 Sep 4.

PMID:
18775008
18.

Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.

Hur C, Broughton DE, Ozanne E, Yachimski P, Nishioka NS, Gazelle GS.

Am J Gastroenterol. 2008 Oct;103(10):2432-42. doi: 10.1111/j.1572-0241.2008.02117.x. Epub 2008 Sep 4.

19.

Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.

Varghese S, Newton R, Ross-Innes CS, Lao-Sirieix P, Krishnadath KK, O'Donovan M, Novelli M, Wernisch L, Bergman J, Fitzgerald RC.

Gastroenterology. 2015 Nov;149(6):1511-1518.e5. doi: 10.1053/j.gastro.2015.07.053. Epub 2015 Aug 3.

PMID:
26248086
20.

Chemoprevention for Barrett's esophagus trial. Design and outcome measures.

Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, Gordon G, Forastiere AA; CBET Research Group.

Dis Esophagus. 2003;16(3):177-86. Review.

PMID:
14641306

Supplemental Content

Support Center